Posted by SLS on October 14, 2015, at 22:21:20
In reply to Re: Conclusions » SLS, posted by Toph on October 14, 2015, at 18:07:27
> Hi Scott
> I don't know how researchers distinguish between drug-induced suicidality and drug-exacerbated suicidality.Just a quick idea...
To be conducted in a research inpatient setting to control for variables, and allow for close observation. Observers would be blinded.
The intake process can establish a baseline rating for the presence of suicidality and violent behavior for an individual. Once the data is collected, each subject is then treated with active compound and followed longitudinally with daily patient ratings. Each patient is evaluated for the emergence of de novo or exacerbation of suicidal thinking. Data on the efficacy and side effects of active compound should be collected as well. Statistics do the rest. The key is to use longitudinal data collection rather than cross-sectional. It should be easy to do. Having a placebo arm would be provide even more data.
Of course, the appropriate intervention protocols will help prevent suicide attempts and completions.
Not bad for 5 minutes' work. I'd rather be selling automobiles, though.
Q: Do you believe that antidepressants can produce suicidality as an adverse side effect?
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1082523
URL: http://www.dr-bob.org/babble/admin/20140902/msgs/1083473.html